• Oxford University and AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine works well as a third booster shot, according to a study, the Financial Times reported citing people familiar with the matter.

• A third booster shot showed "strong enough against any variant," despite concern that the immune system might fight off the adenovirus used as a delivery mechanism.

• Some scientists have feared that repeated use of the adenovirus vector - an inactivated cold virus - could stop the immune system from recognizing the virus's spike protein.

• However, the study found the participants' immune systems reacted to the adenovirus used to deliver the protein. Still, it had a far more significant reaction to the protein, according to the FT.

• It is not known when Oxford and AstraZeneca plan to publish study data, the paper added.

• Price Action: AZN shares are up 0.21% at $56.11 during the premarket session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• G20 Countries Water Down US Push For COVID-19 IP Waiver: Reuters

• Oxford BioMedica To Manufacture More Doses Of AstraZeneca's COVID-19 Vaccine, Upgrades 2021 Outlook

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.